Bristol-Myers Squibb Co- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Bristol-Myers Squibb Co 公司

公司简介

公司代码BMY

公司名称Bristol-Myers Squibb Co

上市日期Jul 05, 1929

成立日期1933

CEODr. Christopher S. (Chris) Boerner, Ph.D.

员工数量34100

证券类型Ordinary Share

年结日Jul 05

公司地址Route 206 And Province Line Road

城市PRINCETON

上市交易所NYSE Consolidated

国家United States of America

邮编08543

电话16092524621

网址https://www.bms.com/in

公司代码BMY

上市日期Jul 05, 1929

成立日期1933

公司高管

名称

名称/职务

职务

持股

持股变动

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

5.33K

+65.41%

Ms. Cari Gallman

Executive Vice President, Corporate Affairs, Member of the Leadership Team

5.01K

+137.97%

Mr. Robert Plenge, M.D., Ph.D.

Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team

--

Mr. Peter J. (Pete) Arduini

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

收入明细

单位: USD更新时间: 3月5日周三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

地区USD

名称

营收

占比

United States

34.10B

70.61%

International

13.19B

27.32%

other

996.00M

2.06%

业务

地区

业务USD

名称

营收

占比

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

股东统计

更新时间: 2月21日周五

持股股东

股东类型

持股股东

股东统计

占比

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

持股股东

股东统计

占比

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

股东类型

股东统计

占比

Investment Advisor

36.81%

Investment Advisor/Hedge Fund

32.60%

Research Firm

2.76%

Pension Fund

2.50%

Bank and Trust

2.25%

Sovereign Wealth Fund

1.85%

Hedge Fund

1.70%

Holding Company

0.23%

Insurance Company

0.16%

Other

19.10%

机构持股

更新时间: 1月19日周日

报告期

机构数

持股数

持股占比

持股变动

2025Q1

4136

1.64B

81.10%

+16.36M

2024Q4

4261

1.64B

81.14%

+17.04M

2024Q3

4116

1.59B

78.69%

-22.72M

2024Q2

4105

1.58B

78.35%

-83.11M

2024Q1

4118

1.64B

80.97%

+13.32M

2023Q4

4115

1.60B

78.83%

-46.38M

2023Q3

4042

1.62B

77.83%

-55.49M

2023Q2

4082

1.65B

78.77%

-34.93M

2023Q1

4110

1.65B

78.74%

-34.09M

2022Q4

4105

1.65B

77.92%

-72.60M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

189.01M

9.31%

+1.40M

+0.74%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

97.01M

4.78%

-7.45M

-7.13%

Dec 31, 2024

State Street Global Advisors (US)

95.14M

4.68%

+2.24M

+2.42%

Dec 31, 2024

JP Morgan Asset Management

63.09M

3.1%

+12.35M

+24.34%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

60.30M

2.97%

-729.92K

-1.19%

Dec 31, 2024

Capital International Investors

45.86M

2.26%

+3.21M

+7.54%

Dec 31, 2024

Geode Capital Management, L.L.C.

44.39M

2.18%

+1.18M

+2.74%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

35.17M

1.73%

+2.58M

+7.91%

Dec 31, 2024

Columbia Threadneedle Investments (US)

28.49M

1.4%

+12.26M

+75.54%

Dec 31, 2024

Fidelity Management & Research Company LLC

27.55M

1.35%

-9.07M

-24.77%

Dec 31, 2024

持股ETF

更新时间: 16 小时前

机构名称

占比

First Trust NASDAQ Pharmaceuticals ETF

8.03%

Invesco S&P Ultra Dividend Revenue ETF

6.78%

NYLI Healthy Hearts ETF

4.96%

iShares U.S. Pharmaceuticals ETF

4.8%

Invesco Pharmaceuticals ETF

4.79%

VanEck Morningstar Wide Moat Value ETF

4.58%

VanEck Pharmaceutical ETF

4.37%

Schwab U.S. Dividend Equity ETF

4.3%

Cullen Enhanced Equity Income ETF

3.79%

SPDR S&P Pharmaceuticals ETF

3.67%

First Trust NASDAQ Pharmaceuticals ETF

占比8.03%

Invesco S&P Ultra Dividend Revenue ETF

占比6.78%

NYLI Healthy Hearts ETF

占比4.96%

iShares U.S. Pharmaceuticals ETF

占比4.8%

Invesco Pharmaceuticals ETF

占比4.79%

VanEck Morningstar Wide Moat Value ETF

占比4.58%

VanEck Pharmaceutical ETF

占比4.37%

Schwab U.S. Dividend Equity ETF

占比4.3%

Cullen Enhanced Equity Income ETF

占比3.79%

SPDR S&P Pharmaceuticals ETF

占比3.67%

分红派息

近5年累计派现 22.71B 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Jun 14, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option

Jul 07, 2023

Aug 01, 2023

Jul 06, 2023

Mar 03, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023

Apr 10, 2023

May 01, 2023

Apr 06, 2023

Dec 08, 2022

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023

Jan 06, 2023

Feb 01, 2023

Jan 05, 2023

Sep 14, 2022

BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022

Oct 07, 2022

Nov 01, 2022

Oct 06, 2022

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Bristol-Myers Squibb Co

59.555USD

Bristol-Myers Squibb Co

59.555

概览

公司